APA (7th ed.) Citation

Zhu, Y., Hu, H., Ding, D., Li, S., Liao, M., Shi, Y., & Huang, J. (2021). First-line pembrolizumab plus chemotherapy for extensive-stage small-cell lung cancer: A United States-based cost-effectiveness analysis. BMC.

Chicago Style (17th ed.) Citation

Zhu, Youwen, Huabin Hu, Dong Ding, Shuosha Li, Mengting Liao, Yin Shi, and Jin Huang. First-line Pembrolizumab Plus Chemotherapy for Extensive-stage Small-cell Lung Cancer: A United States-based Cost-effectiveness Analysis. BMC, 2021.

MLA (8th ed.) Citation

Zhu, Youwen, et al. First-line Pembrolizumab Plus Chemotherapy for Extensive-stage Small-cell Lung Cancer: A United States-based Cost-effectiveness Analysis. BMC, 2021.